<DOC>
	<DOCNO>NCT02335814</DOCNO>
	<brief_summary>This first-in-human ( FIH ) clinical trial Phase 1/1b , open-label , sequential-group , dose-escalation cohort expansion study evaluate safety , PK , PD , antitumor activity FLX925 subject relapse refractory AML .</brief_summary>
	<brief_title>First-in-Human Study FLX925 Subjects With Relapsed Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>1 . Males females age ≥ 18 yr ; 2 . Subjects histologically confirm AML fail prior induction therapy relapse prior therapy ; 3 . Assessment FLT3 mutation status ; 4 . Part 2 ( Expansion ) : Subject must able stratify 1 3 cohort : Cohort A : Subjects FLT3 mutation ( ITD D835 ) prior FLT3 inhibitor treatment Cohort B : Subjects FLT3 mutation ( ITD D835 ) without prior FLT3 inhibitor treatment Cohort C : Subjects without FLT3 mutation time enrollment 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 ; 6 . Considered investigator appropriate candidate Phase 1 clinical study ; 7 . In absence rapidly progress disease , interval prior treatment time initiation FLX925 administration ≥ 2 week cytotoxic agent ≥ 5 halflives investigational/noncytotoxic agent . For patient rapidly proliferative disease , use hydroxyurea allow start prior initiation study therapy ; 8 . Clinically significant toxic effect prior antitumor therapy ( except hydroxyurea ) resolve Grade ≤ 1 start study therapy ( bone marrow parameter [ Grade 1 4 permitted ] ) ; 9 . Serum AST ALT ≤ 3 x ULN ; 10 . Serum bilirubin ≤ 2 x ULN unless due Gilbert 's syndrome hemolysis consider related leukemia ; 11 . Serum creatinine ≤ 1.5 mg/dL calculate creatinine clearance ( CrCl ) ≥ 60 mL/hour CockroftGault equation ; 12 . Normal coagulation profile evidence PT aPTT ≤ 1.5 x ULN ; 13 . For woman childbearing potential , negative serum pregnancy test ; 14 . Women childbearing potential sexually mature male must agree use medically accept method contraception throughout study 30 day follow last dose ; 15 . Ability swallow tablet without difficulty ; 16 . Willingness comply schedule visit , drug administration plan , protocolspecified bone marrow biopsy ; 17 . Written informed consent must provide . 1 . Subjects AML first relapse follow remission &gt; 12 month duration eligible standard therapy ; 2 . Leukemic blast count &gt; 50,000 ; 3 . Active , symptomatic central nervous system ( CNS ) leukemia ; 4 . History another malignancy except follow : adequately treat local nonmelanoma skin cancer ; situ cervical carcinoma ; adequately treat , papillary , noninvasive bladder cancer ; asymptomatic prostate cancer without know metastatic disease requirement therapy require hormonal therapy normal prostate specific antigen ≥ 1 year prior start study therapy ; adequately treat Stage 1 2 cancer currently complete remission , cancer complete remission ≥ 2 year . 5 . Clinically significant cardiovascular disease ; 6 . Significant screen electrocardiogram ( ECG ) abnormalities ; 7 . Significant risk bleed due active peptic ulcer disease bleed diathesis requirement systemic anticoagulation history significant gastrointestinal , urological , intracranial significant bleeding within 1 year start treatment ; 8 . Significant active gastrointestinal disease might impair absorption study therapy ; 9 . Evidence ongoing , uncontrolled systemic infection uncontrolled local infection require therapy time start study therapy 10 . Known suspected human immunodeficiency virus ( HIV ) infection patient HIV seropositive ; 11 . Patients know positive hepatitis B active hepatitis C infection ; 12 . Any evidence ongoing graftversushost disease ( GVHD ) subject prior progenitor cell transplantation ; 13 . Pregnancy breastfeeding ; 14 . Major surgery within 4 week start study therapy ; 15 . Ongoing immunosuppressive therapy within 14 day prior start study therapy ; 16 . Subjects currently receive treatment medication follow potential property either discontinue switched different medication : potential prolong QT interval , strong CYP3A4 inhibitor , CYP3A4 CYP2C19 P glycoprotein ( Pgp ) breast cancer resistance protein ( BCRP ) substrates narrow therapeutic index ; 17 . Concurrent participation another therapeutic clinical trial ; 18 . Any condition deem investigator likely interfere subject 's ability participate clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>